Transgene will present its therapeutic vaccines to investors on October 6
Strasbourg-based biotech company Transgene announced on October 1, 2026 that its management team will meet with institutional investors at an event organized in Paris. This will be an opportunity for the company to present the progress of candidates from its personalized therapeutic vaccine platform.
A meeting with institutional investors on October 6
Transgene announced that its management team will participate in the next edition of the Investor Access Event, organized by Investor Access, on October 6, 2026 in Paris. These events bring together listed companies with institutional investors through targeted meetings with management teams.
According to the company, the 2026 program brings together more than 190 professional investors and 90 listed companies across all of its events.
Myvac platform candidates at the heart of the presentation
During this event, Transgene will present advances in candidates from its Myvac platform, namely TG4050 in head and neck cancer and TG4070 in non-small cell lung cancer, as well as other programs based on viral vectors.
TG4050 is described by the company as its flagship candidate and the first personalized treatment derived from the Myvac platform, having demonstrated clinical proof of concept in patients with head and neck cancer treated in the adjuvant setting. TG4070 is in phase 1 of clinical development in the adjuvant setting in patients with non-small cell lung cancer.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: 9M 2026
Guidance from the release
Under current plans, the company has sufficient cash to ensure financial visibility until early 2028
Risks mentioned
L'activité repose sur le succès de essais cliniques en phase 1/2 pour TG4050 et TG4070, avec résultats finaux attendus fin Q1 2028
La dépendance à l'égard du crédit d'impôt recherche (CIR) : €3,9 M sur €4,3 M d'operating income, soit 91% de ce résultat
Consommation de trésorerie continue : €29,5 M en 9 mois 2026, limitant la visibilité au-delà de début 2028
Opportunities identified
Publication positive de TG4050 dans Nature Communications confirmant 100% DFS après 3+ ans, validant le modèle clinique
Expansion de la plateforme myvac® avec lancement de TG4070 en phase 1 combinée nivolumab dans le poumon (NSCLC)
Capacités de production en phase 3 prêtes fin 2027 et clarté financière jusqu'à début 2028 pour financer les développements
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.